<p><strong>紐約，紐約 / ACCESS Newswire /2025 年 5 月 18 日/</strong> 如果您在 <strong>西氏醫藥服務公司</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
<p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
<p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
<p><strong>訴訟：</strong> 針對西氏醫藥服務公司提起了一項集體訴訟，旨在追回在 2023 年 2 月 16 日至 2025 年 2 月 12 日期間因涉嫌證券欺詐而受到不利影響的股東的損失。</p>
<p><strong>案件詳情：</strong> 提起的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(a) 儘管聲稱對客户需求有強烈的可見性，並將逆風歸因於暫時的 COVID 相關產品去庫存，西氏實際上在其高利潤的 HVP 產品組合中經歷了顯著且持續的去庫存；(b) 西氏的 SmartDose 設備，原本被定位為高利潤增長產品，由於運營效率低下，對公司的利潤率造成了高度稀釋；(c) 這些利潤壓力帶來了昂貴的重組活動風險，包括公司退出與長期客户的連續血糖監測合同；(d) 因此，被告對公司業務、運營和前景的積極陳述在實質上是虛假和/或誤導的，或缺乏合理依據。</p>
<p><strong>接下來怎麼辦？</strong> 如果您在相關時間段內在西氏醫藥服務公司的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
<p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中建立了成功記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往結果不保證類似結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>紐約，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>電話：(212) 363-7500</p>
<p>傳真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>

西氏醫藥服務

<p>針對西氏醫藥服務公司（West Pharmaceutical Services, Inc.，股票代碼：WST）提起了一項集體訴訟，指控其在 2023 年 2 月 16 日至 2025 年 2 月 12 日期間對股東進行證券欺詐。訴狀聲稱，該公司就其財務健康狀況和運營效率做出了虛假陳述，特別是關於其高利潤產品和利潤率的情況。在此期間遭受損失的股東被鼓勵聯繫 Levi & Korsinsky LLP 以尋求潛在的賠償選項</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / May 18, 2025 /</strong> If you suffered a loss on your <strong>West Pharmaceutical Services, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>紐約，紐約 / ACCESS Newswire /2025 年 5 月 18 日/</strong> 如果您在 <strong>西氏醫藥服務公司</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
</div><p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against West Pharmaceutical Services, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025.</p>
<div class="lb-trans"><p><strong>訴訟：</strong> 針對西氏醫藥服務公司提起了一項集體訴訟，旨在追回在 2023 年 2 月 16 日至 2025 年 2 月 12 日期間因涉嫌證券欺詐而受到不利影響的股東的損失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with longstanding customers; and (d) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.</p>
<div class="lb-trans"><p><strong>案件詳情：</strong> 提起的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(a) 儘管聲稱對客户需求有強烈的可見性，並將逆風歸因於暫時的 COVID 相關產品去庫存，西氏實際上在其高利潤的 HVP 產品組合中經歷了顯著且持續的去庫存；(b) 西氏的 SmartDose 設備，原本被定位為高利潤增長產品，由於運營效率低下，對公司的利潤率造成了高度稀釋；(c) 這些利潤壓力帶來了昂貴的重組活動風險，包括公司退出與長期客户的連續血糖監測合同；(d) 因此，被告對公司業務、運營和前景的積極陳述在實質上是虛假和/或誤導的，或缺乏合理依據。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in West Pharmaceutical Services, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下來怎麼辦？</strong> 如果您在相關時間段內在西氏醫藥服務公司的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中建立了成功記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往結果不保證類似結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>紐約，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>電話：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div>

因證券違規行為，西氏醫藥服務公司（WST）被提起集體訴訟 - 請立即聯繫 Levi & Korsinsky